投融资数据库
免费查数据
注册送3天会员
首页>投融资
Enveda
D轮
Enveda Biosciences is a biotechnology company engineering new drugs from plants. Its platform applies cutting-edge advancements in knowledge graphs, metabolomics, and machine learning to discover the next generation of small molecule therapeutics.In April 2023, Enveda Biosciences closed an additional $51 million equity financing to add to the $68 million Series B announced in December 2022.In December 2022, the company closed an equity and debt financing of $68-million.In June 2021, Enveda Biosciences announced an oversubscribed $51M Series A funding round
基本信息
-
公司全称Enveda Biosciences
-
类型小分子疗法研发商
-
产业领域医药研发/制造、化学&生物药
-
公司人数15~50人
-
地址1880 S Flatiron Court,Ste K, BOULDER COLORADO 80301; US; Telephone: +14153235252;
-
联系电话+1-415-323-5252
-
邮箱info@envedabio.com
-
成立时间2019-01-01
投融资
-
2025-09-04
-
2025-02-26
-
2024-11-22
-
2024-06-14
-
2023-04-20
-
2022-12-21
-
2022-12-21
-
2021-06-22
-
2020-10-16
- 加载更多
相关投融资企业
E~PreIPO
Arthrosi Therapeutics LLC focuses on the treatment of uric acid levels and reduce joint damage for people living with gout.In July 2023, Arthrosi Therapeutics secured of $75 million in Series D financing
E~PreIPO
Arthrosi Therapeutics LLC focuses on the treatment of uric acid levels and reduce joint damage for people living with gout.In July 2023, Arthrosi Therapeutics secured of $75 million in Series D financing
收并购
Kronos Bio, Inc.于2017年6月2日根据特拉华州法律成立。该公司是一家临床阶段的生物制药公司,致力于发现和开发新的癌症疗法,旨在通过针对失调转录的精确药物策略来改变患者的预后。